Cutaneous blood flow and adrenoceptor response increase in segmental-type vitiligo lesions.
It has been proposed that two types of vitiligo exist from the physiological and clinical points of view. Nonsegmental-type vitiligo is associated with autoimmune diseases while segmental-type vitiligo results from the dysfunction of sympathetic nerves in the affected area. Using laser Doppler flowmetry and iontophoresis for cutaneous microcirculatory assessments, we evaluated these two types of vitiligo in regard to their physiological changes. Ten patients with facial stable stage segmental-type vitiligo and ten stable nonsegmental-type vitiligo patients were selected for this study. Our results revealed that a nearly threefold increase in cutaneous blood flow was noticed in segmental-type vitiligo as compared to contralateral normal skin. In contrast, a 1.4-1.5 times difference was found among nonsegmental-type vitiligo, lesion side clinically normal skin and contralateral normal skin. There was a significant increase in cutaneous alpha- and beta-adrenoceptor response in segmental-type vitiligo lesions. However, no change in plasma catecholamines or adrenoceptor densities on blood cells was noticed. Our findings suggest that a dysfunction of the sympathetic nerves exists in the affected skin and plays a role in the pathogenesis of segmental-type vitiligo.
Wu
C S
CS
Department of Dermatology, Kaohsiung Medical University, 100 Shih Chuan 1st Road, Kaohsiung, Taiwan.
Yu
H S
HS
Chang
H R
HR
Yu
C L
CL
Yu
C L
CL
Wu
B N
BN
D000293:Adolescent; D000328:Adult; D001783:Blood Flow Velocity; D016022:Case-Control Studies; D002648:Child; D003000:Clonidine / Q000494:pharmacology; D004837:Epinephrine / Q000097:blood; D005260:Female; D006801:Humans; D017078:Laser-Doppler Flowmetry; D008297:Male; D009638:Norepinephrine / Q000097:blood; D010656:Phenylephrine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000502:physiology*; D011943:Receptors, Adrenergic, beta / Q000187:drug effects / Q000502:physiology*; D012867:Skin / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology; D014820:Vitiligo / Q000097:blood / Q000503:physiopathology*
D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D010656:Phenylephrine; D011433:Propranolol; D003000:Clonidine; D009638:Norepinephrine; D004837:Epinephrine